Saturday, October 31, 2026

Rockwell Automation Stock Went Down By Over 9% So Far On Tuesday

Rockwell Automation Stock Went Down By Over 9% So Far On Tuesday

Rockwell Automation (NYSE: ROK), a leading provider of industrial automation and digital transformation solutions, experienced a substantial drop in its shares on Tuesday. Despite two consecutive sessions of share gains, their price fell 9.46% to $248.48, compared to an overall decline of just 0.24% for the NYSE.

Performance Details

The company's shares closed at $263.29 yesterday, representing a decline of 3.51% from its 52-week high of $273.52. Despite servicing diverse geographic regions such as North America, Europe, Middle East Africa, Asia Pacific, and Latin America, it seems that the current trading trend for Rockwell may be somewhat negative. The company's clientele spans various industry verticals, including automotive, semiconductor, warehousing, logistics, and the renewable energy sectors.

Financial Status

Rockwell Automation reported a trailing twelve-month earnings per share (EPS) of $13.35. Investors currently pay $26.83 for every $1 of annual earnings they receive, as indicated by the company's astronomically high trailing twelve-month P/E ratio of 26.83.

Return on Equity

The company's trailing twelve-month performance suggests strong financial health, with a remarkable return on equity (ROE) rate of 40.98%. This profit margin reflects the company's earnings against its shareholders' equity investment. However, the recent decline in share prices suggests a potential shift in investor sentiment. As such, it will be important to closely monitor this company over time.

More news about Rockwell Automation (ROK).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com